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Highlights 
 
 Descending controls alter the gain in the processing of nociceptive inputs  
 The monoamines have major and complex modulatory roles in the descending controls 
 Understanding descending modulation is essential for development of new analgesics 
 
Abstract 
 
Specific primary afferent fibres termed nociceptors are responsible for transmitting nociceptive 
information. Centrally the axonal terminals of these fibres synapse with secondary projection 
neurones in the spinal dorsal horn to transmit nociceptive information to the higher centres in 
the brain. Irrespective of the presence or absence of nociceptive inflow the activity of dorsal 
horn neurones is modulated by, amongst other things, local interneurones and descending 
midbrain and brainstem networks which can inhibit or facilitate dorsal horn transmission. 
These pathways therefore set the threshold for information inflow to the CNS. This review 
article summarises the anatomy, physiology and pharmacology particularly of these 
descending inhibitory and facilitatory pathways and explains why the study of descending 
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 modulation is essential if we are to develop more efficacious interventions for treating pain and 
relieving suffering. 
 
Keywords: Analgesia; DNIC; Nociception; Pain modulation  
Introduction  
Much of what we know about pain to date has been discovered utilising various 
pharmacological and neurophysiological techniques in animal models and these discoveries 
have more recently been confirmed with genomics and advanced imaging. Nociceptors 
transmit information from the periphery to the dorsal horn of the spinal cord. Here the axonal 
terminals synapse with secondary projection neurones which then transmit nociceptive 
information to higher centres in the brain. The activity of these dorsal horn neurones is 
modulated by, amongst other things, local interneurones and descending midbrain and 
brainstem networks which can inhibit or facilitate dorsal horn transmission. These pathways 
therefore set the threshold for information inflow to the CNS. Neurophysiological modalities, 
such as electroencephalography (EEG), bispectral index (BIS), nociceptive withdrawal 
reflexes (NWRs) and somatosensory evoked potentials (SEP) have been used to study both 
afferent ascending and descending pain pathways and cortical representation of pain (Murrell 
and Johnson, 2006). Whilst some may argue that it is preferable to use behavioural outcome 
measures in conscious animals in order to better capture behavioural/learned and homeostatic 
mechanisms in response to a noxious insult, anaesthetized animal models can reduce the 
subjectivity and bias associated for example with quantifying a withdrawal response. 
Nonetheless, the emphasis in both anaesthetized and conscious patients, particularly in the 
study of chronic pain, should be that an appropriate parameter is measured (Mogil and Crager, 
2004), but we are still some way off having a validated set of tools for testing all components 
of the pain experience. This review focuses particularly on the anatomy, physiology and 
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 pharmacology of the descending inhibitory and facilitatory pathways highlighting potential 
targets for pain modulation in animals and man. 
 
 
Studying pain electrophysiologically 
 Electroencephalography provides a unique insight into how the nociceptive pathways 
contribute to pain perception. This technique utilises electrodes placed at various locations on 
the head producing the summated electrical activity of populations of neurones and glial cells 
(Murrell et al., 2005; 2008).  Electroencephalography has numerous research and clinical 
applications (Teplan, 2002). The technique can be used in humans and animals to measure 
anaesthetic depth and antinociceptive effect of different drugs during anaesthesia (Rampil and 
Matteo, 1987; Johnson and Taylor, 1998). For example in ponies undergoing halothane 
anaesthesia, lidocaine obtunded the EEG median frequency (F50) change, which is the 
frequency below which 50% of the power of the EEG is located, that occurred with surgical 
castration illustrating the use of intraoperative EEG monitoring and examination of F50 during 
application of a noxious surgical stimulus as a tool to investigate the antinociceptive action of 
different agents (Murrell et al., 2003; 2005). Direct recording of the activity of individual 
neurones during application of a noxious or non-noxious stimulus can provide information 
about the intensity, quality, duration and velocity of the stimulus and may involve recording 
from peripheral afferent sensory fibres or from dorsal horn wide dynamic range (also known 
as convergent) neurones (Dickenson and Le Bars, 1983; Bee and Dickenson, 2007; Kelly et 
al., 2012). Recording of NWRs is also an established neurophysiological technique consisting 
of applying a noxious stimulus, for example to the limb of an animal, and measurement of 
electromyographic (EMG) activity in muscles contributing to limb withdrawal (Levinsson et 
al., 1999; Clarke et al., 1992; Clarke and Harris, 2004). The withdrawal response, far from 
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 being a simplistic monolithic reflex, is a modular combination of reflexes to individual muscles 
arranged in a matrix to best withdraw or remove the limb from the inciting injury (Harris and 
Clarke, 2003; 2007). NWRs can be used as a direct measure of spinal cord hyperexcitability 
and thus a biomarker of central sensitization (Harris and Clarke, 2007). Central sensitization is 
defined as an increase in excitability of neurones in the central nociceptive pathways to normal 
or subthreshold input (Loeser and Treede, 2008), and is manifest as altered pain sensitivity 
(Woolf, 2011). In models of persistent pain, central sensitization causes a decrease in the 
threshold required to elicit an EMG response and is also characterized by enhanced temporal 
summation of NWRs, which describes an increased perception of pain in response to repetitive 
painful stimuli; both measures are used to evaluate changes in spinal cord nociceptive 
processing (Kelly et al., 2013). These techniques are used in rodents during anaesthesia, but 
NWR thresholds and temporal summation have also been measured in awake and anaesthetized 
dogs and horses using electrical stimuli to evaluate central sensitization, study the 
pharmacology of descending controls and characterise antinociceptive effects of analgesic 
drugs (Peterbauer et al. 2008; Bergadano et al. 2009; Levionnois et al. 2010; Hunt et al. 2016).  
 
The spino-bulbo-spinal loop 
A pain experience consists of both a somatosensory component and a psychological, 
affective component. The term nociception refers to the neural activity in the peripheral and 
central nervous system caused by a painful stimulus and the term pain itself is used to describe 
both this and the emotional and autonomic responses to the insult.  These different components 
of pain are processed in separate, discrete areas of the brain. In most cases the nociceptive 
insult is the cause of pain, but this insult may be absent and its magnitude is not linearly related 
to the pain that is reported or behaviours that are displayed (Loeser and Treede, 2008). This is, 
in part, a consequence of a feedback loop between the brain and spinal cord. This spino-bulbo-
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 spinal loop can alter the extent to which pain signals are amplified or inhibited within the spinal 
cord.  
Painful stimuli are sensed by a diverse range of nociceptor terminals, and initiate action 
potentials that travel along nociceptive afferents (non-myelinated C fibres or small diameter 
myelinated A delta fibres) which synapse with nociceptive specific (NS) cells in laminae I-II 
of the superficial dorsal horn, with a small number terminating deeper in the spinal cord. In 
contrast transmission of innocuous stimuli is predominantly through large diameter, 
myelinated A beta fibres which terminate predominately in laminae III-VI, hence within these 
laminae are proprioceptive neurones responding exclusively to touch. A third class of neurone, 
known as wide dynamic-range (WDR), can receive input from A delta, A beta or C fibres and 
responds in a graded manner (i.e. frequency of action potentials) from low through to high 
threshold noxious input. It is within the spinal cord that substantial transformation and 
modulation of the nociceptive signal can occur before it ascends to higher centres (Kayalioglu, 
2009), due to discrete populations of intrinsic interneurones that can alter responses of NS and 
WDRs neurones, and astrocytes and microglia are also modulatory, particularly in disease 
states (Hains and Waxman, 2006; Scholz and Woolf, 2007; Ji et al., 2013). The ascending tracts 
are usually defined according to where they terminate in the brain (Dostrovsky and Craig, 
2013). Briefly, the spinothalamic tract (terminating in the thalamus) integrates the thalamic 
traffic (and other signals) and is responsible for the discriminative/localisation component of 
pain via projections to the sensorimotor cortex, insular cortex and the anterior cingulate (Purves 
et al., 2001; Dum et al., 2009). The other major ascending partner tract is the spinobulbar tract 
(terminating in both the hindbrain and midbrain regions associated with pain processing) and 
this conveys the affective/intensity component, and projects to the amygdala and hypothalamus 
via the parabrachial nucleus (Craig, 2003). This spinobulbar pathway can influence and recruit 
descending pathways via the periaqueductal grey, pontine locus coeruleus and 
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 rostroventromedial medulla, thereby dictating the output passing through the spinal cord 
(Benarroch, 2008; Waters and Lumb, 2008)  
 
Anatomy of the descending pathways 
One of the most important structures associated with the descending pain control 
system is the region located around the aqueduct of Sylvius known as the periaqueductal grey 
matter (PAG) (Behbehani, 1995; Keay and Bandler, 2015). The PAG assimilates information 
from the somatosensory and cingulate cortices, the thalamus, amygdala and hypothalamus as 
well as directly receiving nociceptive input from the ascending pathways. However, although 
there is evidence for the PAG having direct projections to the spinal cord (Mantyh and 
Peschanski, 1982) spinal analgesia following its stimulation is considered to be due to its 
projections to the nucleus raphe magnus (NRM) and neighbouring structures of the rostral 
ventromedial medulla (RVM) (Vanegas and Schaible, 2004; Heinricher et al., 2009). In 
general, the descending pathways ascendancy can be considered to originate at the 
periaqueductal grey-rostral ventromedial medulla (PAG-RVM) and the ventrolateral medulla 
(Basbaum and Fields, 1979). Within the spinal cord the descending inhibitory influences are 
arranged in the dorsolateral funiculi with the facilitatory influences tending to be centred in the 
ventral/ventrolateral cord (Zhuo & Gebhart 1997; Zhuo & Gebhart 1990).  The PAG-RVM 
exerts a degree of selective inhibition of C fibre mediated nociceptive impulses, but preserves 
A fibre messages coding sensory and discriminatory information (Lu et al., 2004; McMullan 
and Lumb, 2006a; Heinricher et al., 2009) and the RVM can be considered the final relay point 
through which facilitation or inhibition of the nociceptive message passes (Villanueva and Le 
Bars, 1995; Calejesan et al., 2000). The degree of inhibition or facilitation of the pain signals 
in some part is controlled in the RVM by at least two different types of neurones known as 
ON-cells and OFF-cells and these cells are inextricably connected to the higher brain centres 
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 involved in a large number of emotions, psychological states, stresses, and pathologies. The 
role of these cells may be more complicated than previously thought (Cleary et al., 2008; Lau 
and Vaughan, 2014; Salas et al., 2016). Despite the overwhelming evidence for the major role 
of the RVM as a relay station, it is without doubt that the descending pathways also require a 
forebrain loop (Millan, 2002). There is also evidence for anterior cingulate cortex (ACC) 
projections regulating spinal neurones (Gu et al., 2015; Kang et al., 2015) and being able to 
selectively modulate the pain experience. The ACC is involved in the processing and 
modulation of pain affect, and offers a further target for manipulating the pain signature. 
Understanding the role the ACC plays requires more sophisticated paradigms rather than 
relying primarily on the reflexive behaviour from an aversive stimulus. The role of the ACC 
and pain processing is comprehensively described in a recent review article (Fuchs et al., 2014). 
The dorsolateral and lateral sector of the midbrain PAG has differential downstream effects on 
the nociceptive reflexes evoked by activity in both the unmyelinated (C-fibre) and the 
myelinated (A-fibre) nociceptors (McMullan and Lumb, 2006a, 2006b). This differential 
control of nociceptive reflexes is also seen following RVM stimulation (Lu et al., 2004) 
demonstrating that these descending endogenous systems have A and C fibre specificity 
offering further complexity but nonetheless attractive targets for analgesia interventions 
(Waters and Lumb, 2008).  In the mature adult rat, descending inhibition is targeted to spinal 
neurones with a strong afferent C fibre input. However, in the first few weeks postnatally the 
system is controlled differently, with greater descending facilitation particularly targeted to the 
A fibre input (Koch and Fitzgerald, 2014). The evolutionary reason proposed for this A fibre 
input is to provide the dorsal horn with low level, non-noxious, tactile input thereby promoting 
a development of the animal’s sensory networks. The switch from facilitation to inhibition as 
the animal matures is primarily dependent on endogenous opioid levels in the RVM (Hathway 
et al., 2009) with GABA and endocannabinoid levels also playing a role (Hathway et al., 2012; 
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 Li et al., 2015). It is possible that immature nervous systems could be at risk of excessive 
sensory overload and peripheral injury in the first few weeks of life where  facilitation is 
favoured (Schwaller et al., 2016). In summary, this balance of inhibition and facilitation of 
descending pathways is a dynamic product of the afferent evoked activity, the age of the 
animal, but also the excitability of the dorsal horn cell too (Koch and Fitzgerald, 2014).  
Notwithstanding the anatomical arrangement, the descending pathways appear to lack 
specificity, influencing all portions of the spinal cord and it is this widespread and intrinsic 
influence that is responsible for the ability to facilitate or inhibit transmission. Indeed, this 
widespread arrangement also results in not only pain perception being affected but other senses 
too, potentially explaining why some chronic pain states have clinical signs distinct from pain 
alone but can manifest with debilitating effects on sleep and other emotions (Tracey, 2010; 
Zhuo, 2016). Moreover, the perception of pain is sensitive to many mental processes therefore 
not exclusively driven by or maintained by the noxious input (Wiech et al., 2008); heightened 
anxiety and fear for example can then often exacerbate the suffering of pain (Wiech and Tracey, 
2009). Human patients with mental disorder comorbidities are less likely to respond well to 
interventions (Dersh et al., 2002), and studies have proved the positive link between pain and 
anxiety, with negative emotions also being able to cause or exacerbate pain (Wiech and Tracey, 
2009). To date much of the research has focussed on anxiety and depression and the expression 
of pain, but recently studies have also investigated anger, worry and frustration as modulators 
of pain (De Vlieger et al., 2006; Eccleston and Crombez, 2007; van Middendorp et al., 2010). 
The affective dimensions of pain are comprehensively covered elsewhere (Rainville et al., 
2005). Chronic pain can impact on many cognitive domains and future research is still required 
to fully understand this relationship (Geisser and Kratz, 2018).  
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 Research is also required to understand pain vulnerability and resilience in chronic pain 
patients and how this determines the symptoms of the sufferer and the ability to prescribe the 
most appropriate and efficacious rehabilitation and treatment (Denk et al., 2014). 
 
The monoamines 
The major descending pathways use the monoamines noradrenaline and 5-
hydroxytryptamine (5-HT; serotonin) as transmitters (Bannister and Dickenson, 2016; Millan, 
2002). These bidirectional monoaminergic systems exert a complex modulating role over the 
outputs of the dorsal horn neurones and the current understanding is that descending control is 
overwhelmingly determined by noradrenaline and serotonin activity. The inhibition or 
facilitation have been shown to be mediated by distinctly different receptors (Zhuo & Gebhart 
1990; Zhuo & Gebhart 1990; Zhuo & Gebhart 1991), and the balance of power between the 
systems is determined by the type of noxious input and the response to it. The vast multiplicity 
of the transmitter pharmacology involved in the descending controls is comprehensively 
covered elsewhere (Millan, 2002). 
 
Noradrenaline 
Noradrenaline was discovered in the brain in the 1950s. It is the major neurotransmitter 
released by sympathetic postganglionic nerve fibres and is involved in autonomic regulation 
of numerous organs. In addition, noradrenaline is involved in modulating nociception (Gyires 
et al., 2009; Pertovaara, 2013, 2006) the majority of descending noradrenergic projections 
originating from the pontine nucleus locus coeruleus and microstimulation of this nucleus was 
shown to produce antinociceptive effects via spinal alpha 2 adrenoceptors (Jones and Gebhart, 
1986). In healthy subjects the noradrenergic system plays a small part in regulating pain 
threshold, with its role becoming more prominent in cases of injury or inflammation 
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 (Pertovaara, 2013). Noradrenaline released from the locus coeruleus is also involved in the 
regulation of vigilance, attention, and cognitive functions but it is still not possible to surmise 
on the net effect of the noradrenergic system on supraspinal structures; evidence exists for both 
anti-nociceptive and pro-nociceptive actions (Llorca-Torralba et al., 2016). However, in the 
main, the central noradrenergic system inhibits pain, and drugs acting on the alpha 2 
adrenoceptor, alone (or as an adjuvant) have proved effective to varying degrees as analgesics, 
in humans and animals e.g. topically applied agonists may have a role in neuropathies 
(Wrzosek et al., 2015), intra-articular administration has reduced postoperative knee pain (Al-
Metwalli et al., 2008) and for patients with intractable cancer pain, intrathecal administration 
has also been effective (Eisenach et al., 1995). The alpha 2 agonists are widely utilised in wild, 
domestic and laboratory animals for sedation, analgesia and muscle relaxation. Continuous rate 
infusions of dexmedetomidine and medetomidine can also be useful as a component of 
multimodal analgesic regimes during anaesthesia  in horses, dogs and cats (Ansah et al., 2000; 
Murrell and Hellebrekers, 2005; Ringer et al., 2007; Valtolina et al., 2009; Kalchofner et al., 
2009).  In general, spinally administered alpha 2 adrenoceptor agonists have an enhanced 
antinociceptive potency in animal models with a persistent injury (Mansikka et al., 1996; Xu 
et al., 1999; Yaksh et al., 1995), and what is becoming clear is that the intensity, duration and 
type of noxious injury will ultimately determine the noradrenergic response (Poree et al., 1998; 
Kingery et al., 2000; Malmberg et al., 2001; Lähdesmäki et al., 2003; Mansikka et al., 2004). 
Likewise, abnormal noradrenergic activity (for example a reduction in the inhibitory 
influences) can contribute to the hypersensitivity seen in models of both acute inflammation 
and nerve injury (De Felice et al., 2011; Green et al., 1998; Rahman et al., 2008; Xu et al., 
1999) hence the interest in the noradrenergic system as a target for analgesics. This central role 
is further evidenced by studies that have demonstrated restoration of diminished noradrenergic 
control after use of a selective noradrenaline reuptake inhibitor following the development of 
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 a neuropathic pain phenotype (Hughes et al., 2015). In these experiments, chronic intrathecal 
reboxetine alleviated the evoked hypersensitivity produced by tibial nerve transection. 
 
Serotonin/5-HT 
Serotonin has a diverse and widespread distribution throughout the body and even 
though most serotonin is located outside of the central nervous system, it is commonly 
considered one of the most important neurotransmitters. Studies have shown that 
approximately 20% of the neurones in the RVM are serotonergic, and there was early evidence 
for 5-HT involvement in descending modulation (Le Bars, 1988). These descending pain 
modulatory pathways arising from the RVM exert a bidirectional influence upon nociception 
through activation of different serotonergic receptors in the spinal cord (Dogrul et al., 2009). 
Both acute and chronic noxious stimuli can activate these RVM 5-HT neurones and increase 
the expression of 5-HT receptors in the spinal cord (Cai et al., 2014; Zhang et al., 2000). The 
5-HT neurones can influence nociceptive processing directly but also indirectly by influencing 
other non-serotonergic neurones involved in the descending pathways. The collaterals of the 
5-HT neurones have been shown to regulate the bidirectional control from the aforementioned 
‘ON’ and ‘OFF’ cells in the RVM (Braz and Basbaum, 2008). Unlike the adrenergic system 
which is largely considered a pain inhibitory system (due to the activation of alpha 2 
adrenoceptors) the serotonergic/5-HT system is more complex with pain inhibition or 
facilitation attributable to different subtypes of 5-HT receptors (Dogrul et al., 2009; Suzuki et 
al., 2004; Viguier et al., 2013); 5-HT2 and 5-HT3 receptors being considered facilitatory and 
5-HT7 and 5-HT2A receptors classified as inhibitory. On balance, it would seem the 
facilitation assumes more influence than the inhibition. 
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 It is also now known that tonic activation of 5-HT (and non 5-HT) mediated brainstem 
facilitatory influences is one of a multitude of contributors to the development and maintenance 
of central sensitization in sustained pain states (Porreca et al., 2002; Urban and Gebhart, 1999). 
 
Dopamine 
The monoamine dopamine also plays a role in descending controls (Bannister and 
Dickenson, 2016) with mesolimbic, mesocortical and nigrostriatal dopaminergic pathways 
identified as capable of modulating (inhibiting) nociception, primarily its affective component 
(Gao et al., 2001; Magnusson and Fisher, 2000) more by influences in the brain rather than 
direct spinal projections per se. The dopamine system is embedded in the pain matrix circuitry 
(Wood, 2008) but also features importantly in the movement system (Cenci, 2007) and in areas 
of the brain associated with reward (Baik, 2013), learning and cognition (Robbins and Arnsten, 
2009; Werlen and Jones, 2015). 
Studies have shown that dopamine therapies may offer promise as analgesics (Evans et 
al., 2008; Park et al., 2016) and play a role in descending modulation of sensory processing 
(Garcá-Ramrez et al., 2014) but efforts to develop dopamine based therapies are complicated 
by its intrinsic role in locomotion, learning and reward. 
 
The role of the opioids 
The descending modulatory pathways can also be considered components of an opioid 
sensitive matrix. Many of the drugs interacting with components of the descending pathways 
influence or mimic the production of endogenously produced opioids, and there is evidence of 
a bulbospinal opioidergic pathway. 
Numerous animals studies have shown that the PAG is one of the major sources of 
opioid mediated inhibition of the ascending nociceptive impulses (Waters and Lumb, 1997). 
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 The PAG receives cortical inputs mediating a ‘top down’ endogenous pain inhibition system, 
and these projections from the PAG extend to the RVM and noradrenergic pontine nuclei which 
in turn modulate nociceptive input at the spinal cord through the aforementioned release of 
noradrenaline and serotonin. It is likely that the communication from the PAG to these 
noradrenergic and serotoninergic fibres can be both direct but also invoked through 
intermediate relays (Odeh and Antal, 2001). Different regions of the PAG have different 
functions; with respect to the descending control of pain, the dorsal-dorsolateral portions of the 
PAG play a role in stress-induced analgesia, which is independent of opioids but depends on 
endocannabinoids; the lateral-ventrolateral portions of the PAG are involved in opioid 
analgesia and analgesia induced by NSAIDs (Vanegas et al., 2010). 
One example of this ‘top down’ modulating pathway is the placebo effect – an analgesic 
construct that can be elicited in certain people that has its mechanisms firmly rooted, but likely 
not limited to activation of the mu opioid receptor and changes in blood flow to these areas; 
particularly the rostral anterior and pregenual cingulate cortices, the dorsolateral prefrontal 
cortex and anterior insular cortex (Petrovic et al., 2010; Zubieta et al., 2005). In the case of 
placebo it is now apparent that other non-opioidergic mechanisms are also likely recruited since 
expectation, reward, learning and memory play a part in this response, and the once simplistic 
view that the mu opioid receptor was solely responsible has been superseded by a complex web 
of interwoven processes (Eippert et al., 2009). The recent finding that opioidergic descending 
pathways are also players in potential interventions such as distraction and hypnosis, offers 
potential for developing further analgesic interventions. Functional magnetic resonance 
imaging (fMRI) studies have shown (particularly in placebo and nocebo studies) that the 
descending pathways are the conduits through which the cognitive influences affect a pain 
experience. This experience is also subsequently modulated by the individual’s control and on-
going response to the pain experience exerted by pre-frontal limbic brain regions 
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 (Krummenacher et al., 2010; Wiech et al., 2008). The exact mechanisms involved in the 
descending controls are not yet fully understood, but a consensus on their importance is without 
doubt and research into recruitment of their endogenous modulating attributes is a worthwhile 
and commendable ambition. 
 
Other transmitters and pathways modulated by or modulating the descending controls 
 
Endocannabinoids  
There is also widespread evidence of endocannabinoid involvement in areas involved 
in the processing of nociceptive inputs (Jenkins et al., 2004). The expression of the 
endocannabinoid receptors, presence of ligands and metabolites is dynamic and dependent on 
the type of pain being expressed offering potentially attractive targets for analgesic 
opportunities (Jhaveri et al., 2007; Sagar et al., 2009) but it is also involved in motor function, 
cognition, and many signalling pathways, making isolation of the analgesic properties of 
molecules without psychoactive side effects a challenging conundrum. It has been shown that 
analgesia produced by NSAIDs in the descending pain control system also requires an 
activation of the CB1 endocannabinoid receptor (Vanegas et al., 2010). Furthermore, numerous 
experiments suggest that opioids, NSAIDs and the cannabinoids in the PAG and RVM interact 
to potentially decrease gamma-aminobutyric acid (GABA)-ergic inhibition and thus enhance 
the descending flow of impulses that inhibit pain as a mechanism of analgesia (Tham et al., 
2005; Guindon et al., 2006; Guindon and Hohmann, 2009) 
There is also evidence that the endocannabinoid system can express adaptive changes in the 
face of persistent pain states such as osteoarthritis  (Sagar et al. 2010) highlighting one of the 
many potential systems to target in the face of spinal hyperexcitability.  
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 GABA and glycine 
Electrophysiological studies have also highlighted a major role for GABA and glycine 
as inhibitory transmitters through their ability to influence descending activity via their 
presence within interneurones. Projections from the PAG also synapse with GABAergic 
spinopetal neurones. These GABAergic or glycinergic projections can inhibit noxious inputs 
into the dorsal horn of the spinal cord, and recent elegant tracer studies have identified that the 
neurones can express either or both neurotransmitters (Hossaini et al., 2012). Their role in 
modulating the noxious input is without doubt but parsing out the exact role of each system 
and how they interact remains unfinished. Studies have also demonstrated that the ON, OFF 
and neutral cells have varying expression of GABA and glycine, but globally the cell 
populations and expression is determined by the context of the pain experience; for example in 
peripheral inflammation the gene expression and the phenotype of the ON and OFF cells was 
altered (Miki et al., 2002). This study demonstrated during continuous neuronal recordings (3–
6.5 h), a phenotypic switch of RVM neurones during the development of inflammation. This 
was characterised by an increase in the percentage of ON and OFF cells and a reduction in the 
percentage of neutral cells, and this phenotypic change was mediated via NMDA receptor 
activation in response to the inflammation (Miki et al., 2002). 
 
Tonic control 
In the absence of nociceptive input spinal nociceptive neurones are under both tonic and 
stimulus evoked descending controls (Gilbert and Franklin, 2001; Sandkuhler et al., 1987). 
Some of the evidence for the tonic control comes from studies investigating the development 
of long term potentiation (LTP) as a model for central sensitization. LTP can be induced in 
anaesthetized rodents by stimulating the spinal dorsal horn neurones with high intensity 
electrical pulses and the effect is manifest as an increased postsynaptic response to a single 
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 stimulus applied to the afferent once a minute. The stimulus used is not representative of a 
natural noxious stimulus, and indeed it is very challenging to elicit LTP in natural 
circumstances. However, in animals that have undergone rostral spinalization, LTP could be 
induced with natural noxious stimuli such as pinch or intense heat. In these cases this is allied 
to primary hyperalgesia and illustrates that spinalization has removed the tonic descending 
inhibitory control (Sandkühler and Liu, 1998). The structures responsible for tonic descending 
inhibition can be probed by destroying the descending serotonergic neurones of the NRM and 
comparing the paw inflammation and withdrawal responses in these lesioned rats compared to 
the normal rats and hyperalgesia was more marked in these rats lesioned 4-14 days earlier (Ren 
and Dubner, 1996). Locus coeruleus lesions also result in an increased hyperalgesia caused by 
carrageenan compared to non-lesioned rats confirming again the loss of tonic descending 
control (Tsuruoka et al., 2004). Characterization of the receptors involved in the tonic control 
mechanisms has also been shown through many elegant experiments using antagonists (Clarke 
and Harris, 2004; Rivot et al., 1987; Soja and Sinclair, 1983). One important caveat to these 
experiments involving discrete lesions and anaesthesia is they may inadvertently overlook the 
contribution of the plasticity of the spinal cord in response to inflammation or indeed the 
differences in the free ranging conscious animal compared to anaesthetized animal, and these 
should be considered when drawing conclusions. 
 
Conditioned pain modulation (CPM) and Diffuse Noxious Inhibitory Control (DNIC) 
Normally in healthy naïve animals and humans, a conditioning noxious stimulus will 
attenuate the response to a test stimulus applied to a remote (extra segmental) body area, a 
phenomenon termed diffuse noxious inhibitory control, (DNIC) (Le Bars et al., 1979) or ‘pain 
inhibiting pain’. DNIC are powerful, long-lasting controls which inhibit spinal as well as 
trigeminal nociceptive neurones  (Dallel et al., 1999; Dickenson et al., 1980). DNIC operate 
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 via a loop with the afferent and efferent pathways coursing through the ventrolateral quadrant 
and the dorsolateral funiculus of the spinal cord (Villanueva and Le Bars, 1995). Early 
experiments have demonstrated that sectioning the spinal cord abolishes DNIC, with supra-
spinal areas such as the caudal medulla and the subnucleus reticularis dorsalis (SRD) involved 
(Bouhassira et al., 1992) and with the spinoparabrachial and the hypothalamic dopaminergic 
descending pathways facilitating the ascending and descending components of the loop 
(Lapirot et al., 2011, 2009).  The monoamines play pivotal roles in DNIC and offer potentially 
attractive targets for interventions (Bannister et al., 2015; Harris, 2016; Lebars, 1979). 
What has become apparent across many different persistent painful conditions (e.g. 
migraine, irritable bowel disease, and idiopathic pain states) is that some humans have been 
shown to have impaired DNIC (Yarnitsky, 2010) thereby suggesting that a DNIC paradigm 
could be used in prediction of chronic pain susceptibility (van Wijk and Veldhuijzen, 2010).  
As previously mentioned the descending pathways consist of inhibitory and facilitatory 
controls; experimentally these opposing pathways can be studied, but in a patient, currently it 
is only possible to infer the aggregate of the descending control, and so the DNIC terminology 
has been superseded by Conditioned Pain Modulation (CPM) for humans. CPM describes the 
phenomenon by which a conditioning stimulus affects the test stimulus, and can be further 
subdivide into non painful, inhibitory and facilitatory CPM (Yarnitsky et al., 2010a). 
Employing CPM tools in human pain research is still in its infancy, but reliability and 
consensus on testing is available (Nir and Yarnitsky, 2015; Yarnitsky et al., 2015). For both 
client owned animals and laboratory animals, there are only a very small number of studies 
published evaluating DNIC, as the methodology is defined and refined in view of the fact that 
the effect of sedation or anaesthesia must be considered because of the necessity to apply a 
potentially aversive stimulus  (Hunt et al., 2016; White et al., 2017). It is likely that evaluation 
of domestic animals suffering from chronic pain will evolve to include but not be limited to 
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 tests of CPM, central sensitization (defined as the reversible increase in excitability of neurones 
in the central nociceptive pathways and manifest as altered pain sensitivity that can be 
measured with quantitative sensory testing), peripheral sensitization (measured with tools 
evaluating allodynia and hyperalgesia) and more comprehensive ethograms. Furthermore, tests 
that can evaluate spontaneous pain behaviours are desirable, in addition to being able to assess 
the complex relationship between chronic pain and quality of life through aspects of sleep, 
mood, cognitive ability, appetite and the negative affect (Mogil, 2009). Despite all of these 
challenges in the non-verbal species, there is more need than ever to correlate the altered pain 
phenotypes that occur in pain states in domestic animals with these clinical behaviours to 
ensure therapy is targeted and efficacious and pain interventions can be better developed.  
 
Delivering Clinical Impact 
The exact role of the descending pathways and downstream transmitters for different pain 
states has yet to be confirmed but consensus is that progress in these areas will lead to 
improvements in pain management. For example, for osteoarthritis (OA), a chronic debilitating 
disease in humans and animals, the treatment remains an unmet need and this is likely due to 
the disease being driven not only by peripheral sensitizing inputs but also by a central 
component. This central sensitization is believed to be responsible for altering the balance in 
the serotonergic and noradrenergic pathways originating in the PAG-RVM and increasing the 
barrage of nociceptive impulses reaching the brain resulting in increased pain. Pre-clinical OA 
studies have demonstrated an increased serotonergic facilitation in the descending pathways 
resulting in increased spinal cord hyperexcitability (Rahman et al., 2009) but also some of the 
aforementioned transmitters such as the endocannabinoids are also altered (Sagar et al., 2010). 
In the vast majority of painful disease states, damage to tissue and/or nerves in the periphery 
is the inciting cause, leading to enhanced transmitter release in the spinal cord and central 
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 sensitization. The central sensitization is then maintained by continuing input from the 
periphery with modulation from inhibitory and facilitatory descending control from the 
midbrain and brainstem. In many cases it is difficult to parse out the degree of central or 
peripheral input so to effectively treat the disease, both the peripheral input and the central 
modulation will need to be addressed to effectively improve the patient’s quality of life. 
Descending controls in acute and chronic pain 
Following even brief injury or noxious stimulation the descending inhibitory pathways 
from the RVM or ACC may be recruited; functionally offering an injured animal an 
evolutionary advantage for example, escaping from a predator. The role of the descending 
facilitation is less clear from both an evolutionary and functional context compared to 
inhibition but maintaining a degree of secondary hyperalgesia as injured tissue heals could be 
beneficial to avoid ongoing damage to the affected area. Descending facilitation is easier 
implicated in abnormal pain states (Wang et al., 2013). This facilitation also seems likely to be 
responsible for the maintenance but not the initiation of neuropathic pain (D’Mello and 
Dickenson, 2008) and is supported by studies evaluating the time course of nerve induced 
hypersensitivity  (Burgess et al., 2002; Vera-Portocarrero et al., 2006).  
Not all animals or humans with persistent disease will go onto develop chronic pain. Predicting 
which patients will suffer is not straightforward, neither is it an inevitability. There are subsets 
of human patients who are more at risk of developing persistent pain states but reliably 
identifying them is challenging, nonetheless an incredibly important paradigm to develop 
(Denk et al., 2014). In many chronic pain states, there is compelling evidence that the sustained 
debilitating effects of the pain are fuelled by inappropriate activity in the descending pathways 
since the pain intensity is often mismatched by the degree of pathology or in widespread pain 
states where the inciting cause is still unclear. From a clinical standpoint in humans, the ability 
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 to identify patients with impaired DNIC/CPM can then result in a more rapid and efficacious 
treatment plan tailored to the individual, targeting the impaired descending pathways (Arendt-
Nielsen and Yarnitsky, 2009; Yarnitsky et al., 2010b). It has been shown that in patients 
suffering from diabetic neuropathy, the baseline CPM correlated with efficacy of the selective 
serotonin-norepinephrine reuptake inhibitor (SSNRI) duloxetine (Yarnitsky et al., 2012). 
DNIC/CPM testing has been shown to be predictive of developing chronic post-operative pain 
for patients undergoing surgery for knee replacement (Petersen et al., 2016) and following 
thoracotomy (Yarnitsky et al., 2008). Altered CPM has also been identified in patients with 
migraine, chronic tension type headaches, medication overuse headache and headache 
following traumatic brain injury too ( Pielsticker et al., 2005; Perrotta et al., 2010, 2013; Defrin, 
2014). Moreover, in one study of cluster type headache, DNIC inhibition was absent during 
the active phase of the disease and evident in the remission phase confirming DNIC 
dysfunction (Perrotta et al., 2013); although whether this is a primary DNIC dysfunction or 
hypothalamic in origin is unknown. Currently assessing DNIC/CPM in veterinary patients is 
uncommon but potentially offers similar benefits to human patients in order to hone treatment 
and improve quality of life. 
 
Conclusions 
The descending control of the spinal nociception has evolved from a simplistic 
construct of the supraspinal and segmental influences having a direct effect on the sensory 
processes and being able to influence the acute or chronic pain experience. We now consider a 
more complex Bayesian matrix where the nociceptive input will be concurrently constrained 
by behavioural/learned/predicted and homeostatic mechanisms as well as the peripheral 
incoming signals. 
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 In conclusion, what we do know is that dynamic shifts in the descending controls alter 
the gain in the processing of nociceptive inputs against the background of experiences, 
emotions and input from the limbic brain. Better understanding of these descending 
mechanisms will surely equip us not only to modulate the persistent pain experience but also 
to design therapies to provide an improved quality of life for both animals and humans. 
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 Figure Legends 
Figure 1 
Schematic diagram of pain pathway from periphery to brain including sagittal midline T2 
weighted MRI images from a dog brain with selected transverse images at the level of the (1) 
thalamus, (2) midbrain and (3) rostral medulla annotated to indicate the anatomical localisation 
of regions involved in descending modulation 
Primary afferent fibres (A-beta, A-delta, and C-fibres) transmit impulses from the periphery 
(osteoarthritic hip joint) to the dorsal horn of the spinal cord. Secondary nociceptive specific 
cells (NS) are predominantly located in the superficial dorsal horn (laminae I–II), with most 
wide dynamic range (WDR) neurones located in the deeper dorsal horn (e.g. lamina V). Lamina 
V neurones in particular project to the thalamus (via the spinothalamic tract) where there are 
subsequent neuronal projections to various cortical regions  which form part of a ‘pain matrix’ 
(primary and secondary somatosensory, insular, anterior cingulate, and prefrontal cortices). 
The descending pathways originate from brainstem nuclei such as the rostral ventromedial 
medulla (RVM) and the locus coeruleus (LC) which are directly influenced by the ascending 
spinobulbar projections and higher centres to modulate spinal processing. 
 
PAG: periaqueductal grey, DRG: dorsal route ganglion, RVM: rostroventromedial medulla, 
LC: locus coeruleus, LS: limbic system, NS: nociceptive specific cells, PB: parabrachial 
nucleus, WDR: wide dynamic range neurones 
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